Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2018-11-14 Earnings Release
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Zakończenie prac nad nowymi formulacjami suplementów diety 1-MNA - Content (PL)
Earnings Release Classification · 99% confidence The document is a formal communication from the Management Board (Zarząd) of PHARMENA S.A. updating the market on the progress of developing and planning the launch of new dietary supplements based on the ingredient 1-MNA, referencing previous reports (raport bieżący nr 23/2018 and nr 22/2018) filed via the ESPI system. It discusses strategic plans, market size estimations (Poland and EU), and the establishment of a subsidiary (Menavitin GmbH). This type of update, detailing business progress, strategic outlook, and market potential, aligns best with a Management Report (MDA), which typically contains management's explanation of business trends and outlook, often following an earnings release or as a significant operational update. It is not a full Annual Report (10-K), a short Earnings Release (ER), or a formal Audit Report (AR). Given the detailed operational and strategic narrative, MDA is the most appropriate classification. FY 2018
2018-11-14 Polish
PHR_Wykaz akcjonariuszy posiad. pow. 5% głosów na NWZ w dniu 26 09 2018
AGM Information Classification · 99% confidence The document is titled 'Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym Walnym Zgromadzeniu Pharmena S.A. w dniu 26.09.2018 r.', which translates to 'List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of Pharmena S.A. on 26.09.2018'. This content explicitly details the results of a shareholder vote at a General Meeting (ZWZ/EGM), listing the major shareholders and their voting percentages. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is short and contains the final results, not an announcement about a future report.
2018-09-28 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na NWZ w dniu 26.09.2018 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text, written in Polish, announces that the Management Board of PHARMENA S.A. is attaching a list of shareholders holding at least 5% of the votes at an Extraordinary General Meeting (Nadzwyczajnym Walnym Zgromadzeniu) held on 26.09.2018. This document explicitly details the results of voting rights distribution among major shareholders following a general meeting. This aligns directly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is short and appears to be an announcement accompanying the detailed results.
2018-09-28 Polish
Strategia wprowadzenia do sprzedaży suplementów diety 1-MNA w Polsce i Europie - Content (PL)
Management Reports Classification · 99% confidence The document is a detailed announcement by the management board ('Zarząd PHARMENA S.A.') outlining a comprehensive business strategy for launching new dietary supplements based on the molecule 1-MNA across Poland and Europe. It discusses market size estimations, branding (MENAVITIN), distribution channels (pharmacies, online), expansion plans (setting up subsidiaries in Italy, France, UK, etc.), and crucially, how the strategy will be financed: 'Emitent zamierza sfinansować powyższe wydatki ze środków z planowanego podwyższenia kapitału zakładowego w drodze emisji akcji serii E z zachowaniem prawa poboru dotychczasowych akcjonariuszy' (The Issuer intends to finance the above expenditures with funds from the planned increase of the share capital through the issuance of Series E shares with pre-emptive rights for existing shareholders). This focus on financing a major strategic initiative through a planned share capital increase strongly points towards a Capital/Financing Update (CAP). While it contains strategic elements often found in an Investor Presentation (IP) or Management Report (MDA), the explicit announcement of the financing method (share issuance) makes CAP the most precise classification.
2018-09-26 Polish
Podpisanie umowy na opracowanie nowych formulacji suplementów diety, opartych o innowacyjny składnik żywności 1-MNA - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is a formal announcement from the Management Board (Zarząd) of PHARMENA S.A. It discusses receiving a signed agreement for developing new dietary supplement formulations based on a novel food ingredient (1-MNA), and the potential impact on the Issuer's revenues. This content relates to business development, strategic initiatives, and potential future revenue streams, but it is not a standard financial report (10-K, IR, ER) or a specific regulatory filing like insider trading (DIRS) or capital change (CAP). It is a general business update that impacts investor perception. Given the options, this type of strategic business development announcement, which is not explicitly covered by other codes (like M&A, DIV, or ER), fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard corporate disclosure, or potentially as a general business update that might be part of an MDA if it were longer and more explanatory. Since it is a specific announcement about a new business line and potential revenue impact, and it doesn't fit the other specific categories well, RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fallback, although it shares characteristics with MDA. Given the brevity and focus on a specific operational agreement with revenue implications, RNS is chosen as the catch-all for significant, non-standard disclosures.
2018-09-19 Polish
Informacja o postępie projektu leku 1-MNA - Content (PL)
Investor Presentation Classification · 95% confidence The document is a formal communication from the Management Board (Zarząd) of PHARMENA S.A. detailing the progress, decisions, and future plans regarding the commercialization and clinical trials (Phase II results, planning for Phase IIB) of their drug candidate, 1-MNA, across several indications (NASH, PAH, cardiovascular risk reduction). It discusses market potential, patent protection, and next steps involving R&D costs and industry discussions. This content strongly aligns with providing detailed operational and strategic updates to investors regarding the core business pipeline, which is characteristic of an Investor Presentation (IP) or a Management Discussion and Analysis (MDA). Given the detailed discussion of clinical trial results, market sizing, strategic decisions on which indications to pursue, and future research plans, it functions as a comprehensive update for investors. Since it is not a formal regulatory filing like a 10-K or a short earnings release (ER), and it contains presentation-style strategic depth, Investor Presentation (IP) is the most fitting category. It is a detailed update, not just an announcement of a report (RPA).
2018-09-04 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.